3
Clinical Trials associated with AKS-452X(TRACER Europe BV)Anti-COVID19 VaccinaTion AKS-452X BOOSTER Study (ACT-BOOSTER study) - ACT-BOOSTER study
Anti-COVID19 VaccinaTion AKS-452 BOOSTER (ACT-BOOSTER Study)
Aim: To investigate if a subcutaneous (s.c.) booster dose of 90 µg of the naked Akston AKS-452 vaccine (AKS-452X) at >= 3 months post initial vaccination, with any of the four registered vaccines, will boost the antibody titer and immune response in human healthy volunteers 4-6 weeks after s.c. injection.
Anti-COVID19 VaccinaTion AKS-452X BOOSTER Study (ACT-BOOSTER study) - ACT-Booster study
100 Clinical Results associated with AKS-452X(TRACER Europe BV)
100 Translational Medicine associated with AKS-452X(TRACER Europe BV)
100 Patents (Medical) associated with AKS-452X(TRACER Europe BV)
100 Deals associated with AKS-452X(TRACER Europe BV)